C12025: Novel Method for Detection of Cardiac Rhythms Using Cardiac EntropyNovelty:
This invention is a method for the analysis of heart rhythms based on entropy of electrocardiographic ventricular activation (RR) and repolarization (QT) for detecting risk of heart arrhythmia.
Value Proposition:
Despite several medical advancements, congestive heart failure is a lethal disease with a high mortality rate ranging between 30-50% among the aging populations. The onset and mechanism of heart failure is complex which causes deleterious remodeling of the physical structure and functioning of the heart itself. The benefits of incorporating cardiac entropy measurements in the form of the parameter EntropyX are listed as follows:
• Alternative and reliable method for risk assessment of congestive heart failure.
• Allows for risk stratification in cases of sudden death and for preemptive treatment to prevent the development of lethal arrhythmias.
• Real-time cardiac rhythm analysis in order to obtain dynamic information regarding prognosis after onset of arrhythmia.
Technical Details:
Johns Hopkins researchers have developed a method for the analysis of heart rhythms based on calculations of the patterns of variability of time series of electrocardiographic ventricular activation (RR) and repolarization (QT) intervals, which is termed as entropy. From the same segments of electrocardiographic data, a new measure "EntropyX" is calculated from relative changes between moments and entropy of RR intervals and compared with those of QT intervals and vice versa over a time scale ranging from seconds to hours. The absolute and relative changes in entropy over a patient's follow up period provide dynamic information regarding risk of arrhythmic death. Hence this method can be used as a predictor of sudden cardiac death due to rising entropy of normal sinus rhythm (NSR), risk stratification for sudden death, real-time rhythm analysis and for delivering preemptive treatment for prevention of development of lethal arrhythmias.
Looking for Partners:
To develop & commercialize the technology as rhythm analysis software that can serve as a biomarker for risk for adverse cardiac-related events.
Stage of Development:
Pre-Clinical
Data Availability:
Clinical studies
Publications/Associated Cases:
Not at this time
